Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Floats Draft Guidelines For Mandatory Registration Of CROs

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a step aimed at tightening laws governing clinical research in India, the Central Drug Standards Control Organization has released its draft guidelines for registration of clinical research organizations in India. The guidelines have been approved by the Drug Technical Advisory Board but stakeholders will be consulted before the Drug And Cosmetics Rules could be amended to incorporate the new framework

You may also be interested in...



Indian Government Applauds 2010 Preventative Efforts That Lead To Drops In AIDS, Polio, TB

MUMBAI - India's Ministry of Health and Family Welfare has highlighted key indicators that point to an overall improvement in the quality and access of national health programs initiated over the past year

Indian Government Applauds 2010 Preventative Efforts That Lead To Drops In AIDS, Polio, TB

MUMBAI - India's Ministry of Health and Family Welfare has highlighted key indicators that point to an overall improvement in the quality and access of national health programs initiated over the past year

Indian Clinical Research Industry Divided Over Mandatory Registration Of Clinical Trials From June 15

NEW DELHI - As the June 15 deadline approaches for India's mandatory registration of clinical trials in a publicly accessible library, the industry is bracing itself to put trial details online with mixed reactions

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel